难治性原发性胆汁性胆管炎治疗新策略  

New Strategy in the Treatment of Refractory Primary Biliary Cholangitis

作　　者：奉白蕾 沈薇[1] FENG Bai-lei;SHEN Wei(The Department of Gastroenterology,The Second Affiliated Hospital of Chongqing Medical University,Chongqing,400010 China)

机构地区：[1]重庆医科大学附属第二医院消化科

出　　处：《系统医学》2019年第8期184-186,共3页Systems Medicine

摘　　要：原发性胆汁性胆管炎(primary biliary cholangitis,PBC)是一种以肝内小胆管损伤为特点的自身免疫性肝病。熊去氧胆酸(ursodeoxycholic acid,UDCA)是治疗该病的一线药物,但约40%患者对其应答不佳,需要探索新的治疗方法。该文就难治性PBC的药物治疗新策略予以综述,包括奥贝胆酸(obeticholic acid,OCA)、贝特类、免疫抑制剂及生物制剂等,这些药物为PBC患者带来新希望,但尚需更多随机对照试验来证实其长期疗效及安全性。Primary biliary cholangitis(PBC) is an autoimmune liver disease characterized by intrahepatic small bile duct injury.Ursodeoxycholic acid(UDCA) is the first-line treatment for this disease,but about 40% of PBC patients respond poorly to UDCA and need to explore new treatments.This article summarizes the new treatment strategies for refractory PBC patients,including obeticholic acid (OCA),fibrates,immunosuppressive agents,and biological agents.These drugs bring new hope to PBC patients,but their long-term efficacy and safety still need to be confirmed by more randomized controlled trials.

关 键 词：原发性胆汁性胆管炎 难治性 治疗 综述 

分 类 号：R575.7[医药卫生—消化系统]